Predicting responses to chemotherapy in the context that matters - the patient.
Guided by the belief that the most important setting for understanding tumor response to drugs is the human patient, we developed a technology called CIVO. CIVO enables analysis of up to 8 therapies simultaneously in a patient's tumor, without inducing systemic toxicity and while maintaining the integrity of the native tumor microenvironment.
Presage Biosciences , Seattle, WA, USA.
Alicia
A
Moreno-Gonzalez
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA; Seattle Children's Hospital, Seattle, WA, USA.
James M
JM
Olson
Presage Biosciences , Seattle, WA, USA.
Richard A
RA
Klinghoffer
Cancer; clinical drug development; human lymphoma; in vivo; microinjection; preclinical; tumor microenvironment; tumor response